Previous studies have also shown that treatment with renin-angiotensin-aldosterone system blockers, inflammation, and secondary hyperparathyroidism could be considered predictors of ESA hyporesponsiveness [35]. This evidence concerns the gene REN and secondary hyperparathyroidism.